rheumatoid arthritis

J&J unveils new obesity, arthritis collaborations, shares its molecule library
J&J unveils new obesity, arthritis collaborations, shares its molecule library
Fierce Biotech
JNJ
obesity
rheumatoid arthritis
molecules
molecule library
drug development
Flag link:
First PhIII trial of AbbVie’s upadacitinib a success
First PhIII trial of AbbVie’s upadacitinib a success
Pharma Times
AbbVie
Upadacitinib
clinical trials
rheumatoid arthritis
Flag link:
Abbvie Vaults First Pivotal Hurdle With Oral RA Candidate
Abbvie Vaults First Pivotal Hurdle With Oral RA Candidate
Seeking Alpha
AbbVie
rheumatoid arthritis
Upadacitinib
Flag link:
Sanofi, Regeneron set Kevzara up for tough rheumatoid arthritis turf battle with $39K list price
Sanofi, Regeneron set Kevzara up for tough rheumatoid arthritis turf battle with $39K list price
Fierce Pharma
Sanofi
Regeneron
Kevzara
rheumatoid arthritis
Flag link:
EMA panel recommends nod for Sanofi, Regeneron's arthritis drug
EMA panel recommends nod for Sanofi, Regeneron's arthritis drug
Yahoo/Reuters
Europe
EMA
Sanofi
Regeneron
rheumatoid arthritis
Kevzara
Sarilumab
Flag link:
Lilly and Incyte's Loss Is AbbVie and Regeneron's Gain
Lilly and Incyte's Loss Is AbbVie and Regeneron's Gain
Motley Fool
Eli Lilly
Inctye
AbbVie
Regeneron
rheumatoid arthritis
FDA
baricitinib
Humira
Flag link:
The FDA shot down a new rheumatoid arthritis drug — and the companies that make the drug are tumbling
The FDA shot down a new rheumatoid arthritis drug — and the companies that make the drug are tumbling
Yahoo/Business Insider
FDA
rheumatoid arthritis
Eli Lilly
Incyte
baricitinib
Flag link:
Eli Lilly and Incyte say FDA failed to approve their rheumatoid arthritis drug
Eli Lilly and Incyte say FDA failed to approve their rheumatoid arthritis drug
Marketwatch
Eli Lilly
Incyte
FDA
rheumatoid arthritis
baricitinib
Flag link:
$5B in Humira sales at stake with Amgen EU approval
$5B in Humira sales at stake with Amgen EU approval
BioPharma Dive
Humira
Amgen
Europe
rheumatoid arthritis
Amgevita
biosimiliars
Flag link:
Pfizer Announces Approval By The China Food And Drug Administration Of XELJANZ®, The First Oral JAK Inhibitor For Adult Patients With Moderately To Severely Active Rheumatoid Arthritis
Pfizer Announces Approval By The China Food And Drug Administration Of XELJANZ®, The First Oral JAK Inhibitor For Adult Patients With Moderately To Severely Active Rheumatoid Arthritis
Yahoo
Pfizer
China
Xeljanz
rheumatoid arthritis
Flag link:
Pfizer Reports Top-Line Results for Rheumatoid Arthritis Treatment Study
Pfizer Reports Top-Line Results for Rheumatoid Arthritis Treatment Study
Yahoo/GuruFocus
Pfizer
rheumatoid arthritis
Xeljanz
Flag link:
Amgen Signs Value-Based Deal for Enbrel (AMGN)
Amgen Signs Value-Based Deal for Enbrel (AMGN)
Investopedia
Amgen
Enbrel
rheumatoid arthritis
Flag link:
Pfizer + relationship expert = RA connection?
Pfizer + relationship expert = RA connection?
BioPharma Dive
Pfizer
rheumatoid arthritis
Xeljanz
Flag link:
Pfizer says rheumatoid arthritis drug is comparable to Humira as combination treatment but not alone
Pfizer says rheumatoid arthritis drug is comparable to Humira as combination treatment but not alone
Marketwatch
Pfizer
Xeljanz
AbbVie
Humira
rheumatoid arthritis
Flag link:
Three kinds of drugs, like those that treat RA and diabetes, drive increase in spending
Three kinds of drugs, like those that treat RA and diabetes, drive increase in spending
Medical Marketing and Media
drug spending
diabetes
rheumatoid arthritis
oncology
Flag link:
Pfizer's New Biosimilar Is Off and Running
Pfizer's New Biosimilar Is Off and Running
Motley Fool
Pfizer
biosimilars
Remicade
JNJ
Inflectra
rheumatoid arthritis
Flag link:
Novartis says court battle will delay its Enbrel copy until 2018 at least
Novartis says court battle will delay its Enbrel copy until 2018 at least
Yahoo/Reuters
Novartis
Enbrel
patents
Erelzi
Amgen
biosimilars
rheumatoid arthritis
Flag link:
Barictinib FDA Delay Only A 'Short-Term Setback' For Eli Lilly, Says Credit Suisse
Barictinib FDA Delay Only A 'Short-Term Setback' For Eli Lilly, Says Credit Suisse
Yahoo/Benzinga
Eli Lilly
baricitinib
rheumatoid arthritis
Flag link:
FDA delays decision on Lilly and Incyte's arthritis drug
FDA delays decision on Lilly and Incyte's arthritis drug
BioPharma Dive
FDA
Eli Lilly
Incyte
rheumatoid arthritis
baricitinib
Flag link:
Migraine drugs may repeat rheumatoid arthritis success
Migraine drugs may repeat rheumatoid arthritis success
Yahoo/Reuters
migraines
rheumatoid arthritis
biologics
Flag link: